SCHEMBL2579658

SCHEMBL2579658

CC(C)(C)OC(=O)N(CCCCCC(=O)O)CCCCCC(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 1/20 0.53
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
TSHR P16473 5/20 0.43
LMNA P02545 2/20 0.43
NFKB1 P19838 1/20 0.43
PMP22 Q01453 1/20 0.43
ALDH1A1 P00352 3/20 0.41
GPR84 Q9NQS5 7/20 0.41
PPARG P37231 7/20 0.41
PPARD Q03181 7/20 0.41
PPARA Q07869 7/20 0.41
HDAC11 Q96DB2 5/20 0.41
PTPN1 P18031 3/20 0.41
TLR2 O60603 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
FABP4 P15090 2/20 0.41
SLC22A6 Q4U2R8 1/20 0.41
SLC22A8 Q8TCC7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16713413 1.00 CA14 (0.53) CA14HDAC1HDAC2HDAC6TSHR
SCHEMBL6510544 0.94 HDAC1 (0.49) CA14HDAC1HDAC2HDAC6TSHR
SCHEMBL31216313 0.94 GPR84 (0.53) CA14TSHRLMNAALDH1A1GPR84
SCHEMBL20262970 0.93 CA14 (0.51) CA14HDAC1HDAC2HDAC6TSHR
SCHEMBL12901425 0.91 CA14 (0.58) CA14HDAC1HDAC2HDAC6TSHR
SCHEMBL20556291 0.90 GPR84 (0.48) CA14TSHRALDH1A1GPR84PPARG
SCHEMBL31504950 0.90 CA14 (0.47) CA14HDAC1HDAC2HDAC6TSHR
SCHEMBL25628395 0.87 CA14 (0.59) CA14HDAC1HDAC2HDAC6TDP1
SCHEMBL16492823 0.87 CA14 (0.51) CA14TSHRALDH1A1GPR84PPARG
SCHEMBL18675283 0.87 CA14 (0.51) CA14TSHRALDH1A1GPR84PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295081-A1 IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY ARCTURUS THERAPEUTICS, INC. 2023-09-21 US disclosed
WO-2023086514-A1 IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY ARCTURUS THERAPEUTICS, INC. (US) 2023-05-19 WO disclosed
US-20110269943-A1 RADIOLABELED ANNEXINS UNIVERSITY OF WASHINGTON (US) 2011-11-03 US disclosed
US-7744853-B2 Radiolabeled annexins PONIARD PHARMACEUTICALS, INC. (US) 2010-06-29 US disclosed
US-7115248-B2 Radiolabeled annexins NEORX CORPORATION (US) 2006-10-03 US disclosed
US-20060029545-A1 Radiolabeled annexins NEORX CORPORATION, REGENTS OF THE UNIVERSITY OF MICHIGAN 2006-02-09 US disclosed
US-6908903-B1 Cluster clearing agents ALETHEON PHARMACEUTICALS, INC. (US) 2005-06-21 US disclosed
US-20050036948-A1 Radiolabeled annexins NEORX CORPORATION (US) 2005-02-17 US disclosed
EP-1426062-A2 Radiolabeled annexins NEORX CORPORATION (US) 2004-06-09 EP disclosed
EP-0918547-B1 RADIOLABELED ANNEXINS NEORX CORP (US) 2004-03-10 EP disclosed
US-20030220233-A1 Radiolabeled annexins NEORX CORPORATION 2003-11-27 US disclosed
US-20020137672-A1 Radiolabeled annexins KASINA SUDHAKAR (US) 2002-09-26 US disclosed
US-6172045-B1 COMPLEX CONTAINING 1-DESOXY-1-THIO-N-ACETYLGALACTOSAMINE NEORX CORPORATION 2001-01-09 US disclosed
US-6171577-B1 ACCESSIBLE SULFHYDRYL GROUP; AND HEXOSE MOIETY RECOGNIZED BY A MAMMALIAN LIVER RECEPTOR, WHEREIN THE HEXOSE MOIETY IS CONJUGATED TO THE ANNEXIN. NEORX CORPORATION 2001-01-09 US disclosed
US-5968477-A IMAGING AGENTS WITH SULFHYDRYL GROUPS AND HEXOSE GROUPS NEORX CORPORATION (US) 1999-10-19 US disclosed
EP-0918547-A2 RADIOLABELED ANNEXINS NEORX CORPORATION (US) 1999-06-02 EP disclosed
WO-1998004294-A2 RADIOLABELED ANNEXINS NEORX CORPORATION (US) 1998-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295081-A1 IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY NSUN3, POLRMT, NPC1L1 CA14 2668/4885HDAC1 703/4885HDAC2 865/4885
US-20060029545-A1 Radiolabeled annexins ANXA11, ANXA1, ANXA3 CA14 740/4885HDAC1 4383/4885HDAC2 4832/4885
US-20050036948-A1 Radiolabeled annexins ANXA11, ANXA1, ANXA3 CA14 740/4885HDAC1 4383/4885HDAC2 4832/4885
US-20110269943-A1 RADIOLABELED ANNEXINS ANXA11, ANXA1, ANXA3 CA14 740/4885HDAC1 4383/4885HDAC2 4832/4885
US-20020137672-A1 Radiolabeled annexins ANXA11, ANXA1, ANXA3 CA14 740/4885HDAC1 4383/4885HDAC2 4832/4885
US-20030220233-A1 Radiolabeled annexins ANXA11, ANXA1, ANXA3 CA14 740/4885HDAC1 4383/4885HDAC2 4832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.